Compare Motorola Solutions Inc (MSI) vs Novavax Inc (NVAX) Price & Performance

Motorola Solutions (MSI) trades at $462.98, down 1.08% today, with strong technical support at $459 and bullish moving averages. The company shows robust fundamentals with Q2 2026 EPS beating expectations at $4.41 vs. $3.85, revenue growth to $11.68B in 2025, and a $2B share repurchase authorization announced September 2026. Recent acquisition of D-Fend Solutions for $1.5B expands counter-drone capabilities.

Outlook remains positive with 70.6% analyst buy ratings and $536.50 consensus price target, representing 16% upside. Risks include elevated valuation multiples (P/E 36.48) and significant capital expenditures driving negative cash flow. The stock offers growth potential through security technology expansion but faces execution risks from recent acquisitions and competitive pressures.

Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.

The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.